SBIR-STTR Award

  1. You are here:    Home
  2. Search Databases
  3. Search SBIR-STTR Awards
  4. SBIR-STTR Award

Novel L-Nucleoside Combination Anti-HBV Therapy
Award last edited on: 3/5/07

Sponsored Program
SBIR
Awarding Agency
NIH : NIAID
Total Award Amount
$1,093,713
Award Phase
2
Solicitation Topic Code
-----
Principal Investigator
Martin L Bryant

Company Information

Idenix Pharmaceuticals Inc (AKA: Novirio Pharmaceuticals Inc)

320 Bent Street Fourth Floor
Cambridge, MA 02139
   (617) 995-9800
   investor@idenix.com
   www.novirio.com
Location: Multiple
Congr. District: 07
County: Middlesex

Phase I

Contract Number: 1R44AI047784-01
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
2000
Phase I Amount
$100,000
This is a new, fast track application that explains the need for additional therapeutics for the treatment of chronic hepatitis B virus (HBV) infection. Discovery of novel non cytotoxic L-nucleosides with potent anti-HBV activity that, when used in combination, act synergistically is described. These L-nucleosides are reported to inhibit the viral DNA polymerase and replication without effect upon cellular polymerases or mitocohndrial function and have been shown to significantly reduce viral load in the chronic woodchuck hepatitis model. Funding from SBIR phase 1 and 2 will be used to select and develop the combination of the L-nucleosides with the greatest potential for commercialization. Phase 1 will determine pharmacology, toxicology and antiviral potency of two and three L nucleoside combinations in the woodchuck chronic hepatitis model. PROPOSED COMMERCIAL APPLICATION: Chronic treatment of Hepatitis B virus infection. Delay in progression to cirrhosis and hepatocellular carcinoma. Possible elimination of Hepatitis B virus

Phase II

Contract Number: 4R44AI047784-02
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
2001
(last award dollars: 2002)
Phase II Amount
$993,713
This is a new, fast track application that explains the need for additional therapeutics for the treatment of chronic hepatitis B virus (HBV) infection. Discovery of novel non cytotoxic L-nucleosides with potent anti-HBV activity that, when used in combination, act synergistically is described. These L-nucleosides are reported to inhibit the viral DNA polymerase and replication without effect upon cellular polymerases or mitocohndrial function and have been shown to significantly reduce viral load in the chronic woodchuck hepatitis model. Funding from SBIR phase 1 and 2 will be used to select and develop the combination of the L-nucleosides with the greatest potential for commercialization. Phase 1 will determine pharmacology, toxicology and antiviral potency of two and three L nucleoside combinations in the woodchuck chronic hepatitis model. PROPOSED COMMERCIAL APPLICATION: Chronic treatment of Hepatitis B virus infection. Delay in progression to cirrhosis and hepatocellular carcinoma. Possible elimination of Hepatitis B virus.